Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating income | -$12.9M | -$19.2M | -$22.9M | -$19.8M | -$27.6M |
| Net income | -$12.9M | -$19.1M | -$22.3M | -$19.0M | -$26.4M |
| EPS (diluted) | -$3.02 | -$1.51 | -$1.43 | -$1.11 | -$1.32 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$9.50M | -$13.6M | -$16.0M | -$12.2M | -$16.0M |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $5.74M | $20.0M | $19.1M | $18.5M | $31.6M |
| Total assets | $6.66M | $20.4M | $19.2M | $18.6M | $31.7M |
| Total liabilities | $2.42M | $6.19M | $6.98M | $8.89M | $13.3M |
| Shareholders' equity | -$11.0M | $14.2M | $12.2M | $9.71M | $18.4M |
| Retained earnings | -$12.9M | -$32.0M | -$54.2M | -$73.2M | -$99.7M |
| Shares (wtd avg diluted) | 4.27M | 12.7M | 15.6M | 17.1M | 21.8M |
Every figure is extracted from Nuvectis Pharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.